

# Patrizia Carrieri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5647412/publications.pdf>

Version: 2024-02-01

235  
papers

7,747  
citations

71102

41  
h-index

66911

78  
g-index

239  
all docs

239  
docs citations

239  
times ranked

9305  
citing authors

#	ARTICLE	IF	CITATIONS
1	Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). Liver International, 2022, 42, 38-49.	3.9	5
2	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). Cannabis and Cannabinoid Research, 2022, 7, 677-689.	2.9	6
3	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
4	Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort). Liver International, 2022, 42, 249-252.	3.9	3
5	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	13.7	257
6	Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER). Harm Reduction Journal, 2022, 19, 2.	3.2	4
7	Peer presence and familiarity as key factors to reduce cocaine intake in both rats and humans: an effect mediated by the subthalamic nucleus. Psychopharmacology, 2022, 239, 1097-1113.	3.1	8
8	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). Clinical Nutrition, 2022, 41, 610-619.	5.0	8
9	Use of psychoactive substances by night-shift hospital healthcare workers during the first wave of the COVID-19 pandemic: a cross-sectional study based in Parisian public hospitals (ALADDIN). BMJ Open, 2022, 12, e055699.	1.9	5
10	Knowledge of liver fibrosis stage among adults with <scp>NAFLD</scp>/<scp>NASH</scp> improves adherence to lifestyle changes. Liver International, 2022, 42, 984-994.	3.9	24
11	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. JHEP Reports, 2022, 4, 100481.	4.9	3
12	HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPATHI) Tj ETQq0,0 0 rgBT /Overlock	1.7	1
13	Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France. PLoS ONE, 2022, 17, e0261069.	2.5	4
14	Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey). Hepatology Communications, 2022, 6, 1005-1015.	4.3	7
15	Impact of the <scp>COVID</scp> â€“19 crisis on healthcare workers: The need to address quality of working life issues. Respirology, 2022, 27, 469-471.	2.3	1
16	Perceived stigma, substance use and self-medication in night-shift healthcare workers: a qualitative study. BMC Health Services Research, 2022, 22, .	2.2	7
17	Stigma and care avoidance in people with unhealthy alcohol use: A call for research and action. Journal of Hepatology, 2022, 77, 1221-1222.	3.7	4
18	Smoking increases the risk of post-acute COVID-19 syndrome: Results from a French community-based survey. Tobacco Induced Diseases, 2022, 20, 1-10.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. Journal of Hepatology, 2021, 74, 37-47.	3.7	21
20	Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France. Liver International, 2021, 41, 2328-2340.	3.9	3
21	Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Expert Review of Anti-Infective Therapy, 2021, 19, 1147-1156.	4.4	6
22	HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). AIDS and Behavior, 2021, 25, 4141-4153.	2.7	8
23	European "NAFLD Preparedness Index"™ Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 2021, 3, 100234.	4.9	27
24	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nature Communications, 2021, 12, 4450.	12.8	67
25	Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis. HIV Medicine, 2021, 22, 924-935.	2.2	2
26	Post-HCV cure self-reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH). Journal of Viral Hepatitis, 2021, 28, 1665-1667.	2.0	2
27	Social vulnerability of patients co-infected with hepatitis B and hepatitis delta viruses: Data from the ANRS CO22 HEPATHER cohort. Journal of Clinical Virology, 2021, 144, 104987.	3.1	2
28	Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). Hepatology, 2020, 71, 1182-1197.	7.3	8
29	Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS FANTASIO study). Addiction, 2020, 115, 573-582.	3.3	16
30	HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort). AIDS and Behavior, 2020, 24, 1069-1084.	2.7	12
31	Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS CO13 HEPAVIH). Journal of Hepatology, 2020, 72, 588-591.	3.7	7
32	Alcohol Use Patterns and Liver Outcomes: Is There Really a Difference Between Drinking Beer and Drinking Wine?. Clinical Gastroenterology and Hepatology, 2020, 18, 1650-1651.	4.4	0
33	Patient-reported outcomes to enhance person-centred HIV care. Lancet HIV, 2020, 7, e59-e68.	4.7	79
34	Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit. European Journal of Gastroenterology and Hepatology, 2020, 32, 1212-1221.	1.6	4
35	Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS Tj ETQq1 1.0.784314 rgBT /Cv	2.0	13
36	Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH). Journal of Viral Hepatitis, 2020, 27, 1462-1472.	2.0	6

#	ARTICLE	IF	CITATIONS
37	Coffee Intake and Neurocognitive Performance in HIV/HCV Coinfected Patients (ANRS CO13 HEPAVIH). <i>Nutrients</i> , 2020, 12, 2532.	4.1	7
38	“Everybody living with a chronic disease is entitled to be cured” Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 81, 102766.	3.3	23
39	Application of Functional Data Analysis to Identify Patterns of Malaria Incidence, to Guide Targeted Control Strategies. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4168.	2.6	4
40	Correlates of Self-Reported Cotton Fever Experience among People Who Inject Opioids. <i>Substance Use and Misuse</i> , 2020, 55, 1021-1027.	1.4	4
41	Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS Tj ETQq1 1 0,784314 rgBT /Overlock 10 TF	2.9	4
42	Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection. <i>Aids</i> , 2020, 34, 953-954.	2.2	5
43	Letter to the Editor: Patient-Reported Outcomes for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: Rationale for Expanded Use. <i>Hepatology</i> , 2019, 70, 443-444.	7.3	1
44	Methadone in primary care in France: Using evidence for action against hepatitis C. <i>International Journal of Drug Policy</i> , 2019, 71, 91-92.	3.3	1
45	France removes hepatitis C treatment prescriber restrictions”But what is the impact of the delay for key populations?. <i>Liver International</i> , 2019, 39, 2418-2419.	3.9	4
46	Prevention and care of hepatitis B in the rural region of Fatick in Senegal: a healthcare workers’ perspective using a mixed methods approach. <i>BMC Health Services Research</i> , 2019, 19, 627.	2.2	12
47	Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. <i>International Journal of Drug Policy</i> , 2019, 72, 61-68.	3.3	23
48	Screening, diagnosis and care cascade for viral hepatitis B and C in Yaoundé, Cameroon: a qualitative study of patients and health providers coping with uncertainty and unbearable costs. <i>BMJ Open</i> , 2019, 9, e025415.	1.9	25
49	Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol. <i>BMJ Open</i> , 2019, 9, e023683.	1.9	9
50	Factors Associated with Virological Rebound in HIV-Positive Sub-Saharan Migrants Living in France After Traveling Back to Their Native Country: ANRS-VIHVO 2006-2009 Study. <i>Journal of Immigrant and Minority Health</i> , 2019, 21, 1342-1348.	1.6	3
51	Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356). <i>BMJ Open</i> , 2019, 9, e030211.	1.9	12
52	No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH) Tj ETQq0 0 0,rgBT /Overlock 10 TF	1.8	2
53	Interventions to address substance use and sexual risk among gay, bisexual and other men who have sex with men who use methamphetamine: A systematic review. <i>Drug and Alcohol Dependence</i> , 2019, 194, 410-429.	3.2	43
54	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , 2018, 68, 402-411.	3.7	105

#	ARTICLE	IF	CITATIONS
55	Reply to: “Coffee consumption and decreased all-cause mortality” What is the true estimate of effect? Journal of Hepatology, 2018, 68, 1106.	3.7	0
56	The need for patient-tailored dosing of baclofen in future clinical trials†. European Neuropsychopharmacology, 2018, 28, 656-657.	0.7	3
57	Importance of the patient-physician interaction in assessing acceptability of HIV cure trials. HIV Medicine, 2018, 19, e56-e57.	2.2	7
58	The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients. Journal of Hepatology, 2018, 68, 845-847.	3.7	9
59	Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in <scp>NS</scp>3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and <scp>HIV</scp> coinfection with and without cirrhosis (<scp>ANRS HC</scp>31 <scp>SOFTRIH</scp> study). HIV Medicine, 2018, 19, 227-237.	2.2	10
60	Impaired patient-reported outcomes persist in <scp>HIV</scp>-<scp>HCV</scp> co-infected patients and in cirrhotic patients despite <scp>HCV</scp> clearance. Journal of Viral Hepatitis, 2018, 25, 314-315.	2.0	2
61	Une analyse de Twitter pour mieux comprendre les acteurs de la communication des nouvelles drogues et leurs discussions. , 2018, , .		0
62	Drug consumption rooms in Catalonia: A comprehensive evaluation of social, health and harm reduction benefits. International Journal of Drug Policy, 2018, 62, 24-29.	3.3	18
63	Wine Consumption and Lower Risk of Advanced Liver Fibrosis: A True Effect or Unmeasured Confounding? A Longitudinal Analysis (ANRS CO13 HEPAVIH Cohort). American Journal of Gastroenterology, 2018, 113, 1729-1732.	0.4	1
64	Changes in supervised drug-injecting practices following a community-based educational intervention: A longitudinal analysis. Drug and Alcohol Dependence, 2018, 192, 1-7.	3.2	8
65	Impact of an educational intervention on risks associated with drug injection, and on psychosocial factors (PSF) involved in initiating and maintaining new health behaviors over time. Addictive Behaviors, 2018, 87, 222-230.	3.0	3
66	Profile, risk practices and needs of people who inject morphine sulfate: Results from the ANRS-AERLI study. International Journal of Drug Policy, 2018, 59, 3-9.	3.3	3
67	Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. PLoS ONE, 2018, 13, e0199874.	2.5	3
68	Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS CO-13 HEPAVIH Cohort). Nutrients, 2018, 10, 705.	4.1	18
69	Factors associated with perceived loss of libido in people who inject opioids: Results from a community-based survey in France. Drug and Alcohol Dependence, 2018, 190, 121-127.	3.2	10
70	Cannabinoids and reduced risk of hepatic steatosis in HIV-HCV co-infection: paving the way for future clinical research. Expert Review of Anti-Infective Therapy, 2018, 16, 377-380.	4.4	3
71	Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (<scp>ANRS CO</scp>13-<scp>HEPAVH</scp>). Journal of Viral Hepatitis, 2018, 25, 171-179.	2.0	23
72	Posttraumatic Stress Disorder as a Significant Correlate of Voluntary Antiretroviral Treatment Interruption in Adult HIV-Infected Patients Followed up in French Hospitals. Journal of Clinical Psychiatry, 2018, 79, .	2.2	3

#	ARTICLE	IF	CITATIONS
73	Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfecting patients. <i>World Journal of Hepatology</i> , 2018, 10, 856-866.	2.0	10
74	Factors Associated with HIV Status Disclosure in HIV-Infected Sub-Saharan Migrants Living in France and Successfully Treated with Antiretroviral Therapy: Results from the ANRS-VIHO Study. <i>Journal of Immigrant and Minority Health</i> , 2017, 19, 843-850.	1.6	9
75	No significant effect of cannabis use on the count and percentage of circulating CD4 T cells in HIV/HCV co-infected patients (ANRS CO13-HEPAVIH French cohort). <i>Drug and Alcohol Review</i> , 2017, 36, 227-238.	2.1	18
76	Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1-10.	3.0	36
77	Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 177-188.	8.1	79
78	Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort. <i>Journal of Hepatology</i> , 2017, 67, 23-31.	3.7	45
79	Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort. <i>Addiction</i> , 2017, 112, 1669-1679.	3.3	10
80	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). <i>Patient</i> , 2017, 10, 605-614.	2.7	4
81	Decrease in self-reported offences and incarceration rates during methadone treatment: A comparison between patients switching from buprenorphine to methadone and maintenance treatment incident users (ANRS-Methaville trial). <i>International Journal of Drug Policy</i> , 2017, 39, 86-91.	3.3	10
82	Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. <i>Journal of Hepatology</i> , 2017, 67, 1157-1167.	3.7	25
83	The negative impact of <sc>HBV</sc>/<sc>HCV</sc> coinfection on cirrhosis and its consequences. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1054-1060.	3.7	66
84	Role of community-based research in advocating <sc>HCV</sc> prevention and care. <i>Journal of the International AIDS Society</i> , 2017, 20, e25005.	3.0	1
85	Thrombosis and antiphospholipid antibody syndrome during acute Q fever. <i>Medicine (United States)</i> , 2017, 96, e7578.	1.0	19
86	Self-Reported Bothersome Symptoms Across Different Socioepidemiological Groups of People Living With HIV Attending French Hospitals: Results From the ANRS-VESPA2 Survey. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 110-119.	1.2	10
87	Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. <i>Harm Reduction Journal</i> , 2017, 14, 19.	3.2	33
88	Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 56-65.	1.5	0
89	Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort). <i>Digestive Diseases and Sciences</i> , 2017, 62, 2943-2944.	2.3	0
90	Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey). <i>PLoS ONE</i> , 2017, 12, e0171645.	2.5	25



#	ARTICLE	IF	CITATIONS
91	Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France. Substance Abuse Treatment, Prevention, and Policy, 2017, 12, 46.	2.2	14
92	Pain in methadone patients: Time to address undertreatment and suicide risk (ANRS-Methaville trial). PLoS ONE, 2017, 12, e0176288.	2.5	7
93	Severe liver disease related to chronic hepatitis C virus infection in treatment-naïve patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014. Eurosurveillance, 2017, 22, .	7.0	9
94	De la recherche communautaire À la transformation sociale: lâ€™exemple du projet ANRS-AERLI sur lâ€™accompagnement et lâ€™éducation aux risques liés À lâ€™injection. Psychotropes (discontinued), 2017, Vol. 23, 57-72.		2
95	Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study. PLoS ONE, 2016, 11, e0157062.	2.5	20
96	Treatment and Prophylactic Strategy for Coxiella burnetii Infection of Aneurysms and Vascular Grafts. Medicine (United States), 2016, 95, e2810.	1.0	25
97	Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). European Journal of Gastroenterology and Hepatology, 2016, 28, 1003-1007.	1.6	7
98	The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the <sc>SIRIUS</sc> study. Liver International, 2016, 36, 42-48.	3.9	50
99	Psychiatric and substance use disorders in <sc>HIV</sc>/hepatitis C virus (<sc>HCV</sc>)â€™coinfected patients: does <sc>HCV</sc> clearance matter? [Agence Nationale de Recherche sur le <sc>SIDA</sc> et les HÃ©patites Virales (<sc>ANRS</sc>) <sc>HEPAVIH CO</sc>13 cohort]. HIV Medicine, 2016, 17, 758-765.	2.2	5
100	A reduced factor structure for the PROQOLâ€™HIV questionnaire provided reliable indicators of health-related quality of life. Journal of Clinical Epidemiology, 2016, 72, 116-125.	5.0	10
101	Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. HIV Clinical Trials, 2016, 17, 63-71.	2.0	4
102	B-cell non-Hodgkin lymphoma linked to Coxiella burnetii. Blood, 2016, 127, 113-121.	1.4	78
103	Tropheryma whipplei DNA in bronchoalveolar lavage samples: a case control study. Clinical Microbiology and Infection, 2016, 22, 875-879.	6.0	24
104	Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRSâ€™AERLI intervention study. Addiction, 2016, 111, 94-106.	3.3	42
105	HIV infection among persons who inject drugs. Aids, 2016, 30, 1858-1859.	2.2	3
106	HIV infection among persons who inject drugs. Aids, 2016, 30, 815-826.	2.2	100
107	Antiphospholipid Antibody Syndrome With Valvular Vegetations in Acute Q Fever. Clinical Infectious Diseases, 2016, 62, 537-544.	5.8	33
108	PASSI d'Argento (Silver Steps): the main features of the new nationwide surveillance system for the ageing Italian population, Italy 2013-2014. Annali Dell'Istituto Superiore Di Sanita, 2016, 52, 536-542.	0.4	7

#	ARTICLE	IF	CITATIONS
109	Securing opioid substitution treatment access and quality for people who inject drugs. <i>Aids</i> , 2015, 29, 975-976.	2.2	1
110	Psychometric assessment of health-related quality of life and symptom experience in HIV patients treated with antiretroviral therapy. <i>Quality of Life Research</i> , 2015, 24, 1407-1418.	3.1	10
111	Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1816-1824.	3.0	39
112	Increasing access to opioid maintenance treatment: The role of primary care in France. <i>International Journal of Drug Policy</i> , 2015, 26, 434-435.	3.3	3
113	Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). <i>Clinical Infectious Diseases</i> , 2015, 61, 40-48.	5.8	21
114	Comparison of risk factors in HIV-infected men who have sex with men, coinfecting or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey). <i>Sexually Transmitted Infections</i> , 2015, 91, 21-23.	1.9	21
115	Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study). <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 701-713.	3.0	4
116	Variations in Cannabis Use Level and Correlates in Opiate-Users on Methadone Maintenance Treatment: A French Prospective Study. <i>Journal of Substance Abuse Treatment</i> , 2015, 58, 100-105.	2.8	10
117	Scaling up combined community-based HIV prevention interventions targeting truck drivers in Morocco: effectiveness on HIV testing and counseling. <i>BMC Infectious Diseases</i> , 2015, 15, 208.	2.9	10
118	Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy (ART): the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort. <i>Antiviral Therapy</i> , 2015, 20, 763-772.	1.0	6
119	Impact of HCV Treatment and Depressive Symptoms on Adherence to Haart among HIV-HCV-Coinfected Patients: Results from the Anrs-Co13-Hepavii Cohort. <i>Antiviral Therapy</i> , 2014, 19, 171-178.	1.0	11
120	Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, S29-S40.	1.2	28
121	Reevaluation of the Risk of Fetal Death and Malformation After Q Fever. <i>Clinical Infectious Diseases</i> , 2014, 59, 256-260.	5.8	37
122	HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions. <i>BMJ Open</i> , 2014, 4, e005694.	1.9	11
123	Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 351-358.	3.0	5
124	Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfecting patients. <i>Aids</i> , 2014, 28, 1155-1160.	2.2	6
125	High Levels of Alcohol Consumption Increase the Risk of Advanced Hepatic Fibrosis in HIV/Hepatitis C Virus-Coinfected Patients: A Sex-Based Analysis Using Transient Elastography at Enrollment in the HEPAVIH ANRS CO13 Cohort. <i>Clinical Infectious Diseases</i> , 2014, 59, 1190-1192.	5.8	15
126	Risk factors for adherence failure in HIV-infected sub-Saharan migrants living in France and travelling back to their native country. <i>International Journal of STD and AIDS</i> , 2014, 25, 389-390.	1.1	3



#	ARTICLE	IF	CITATIONS
127	Correlates of general practitioners'™ recommendations to patients regarding vaccination for the 2009-2010 pandemic influenza (A/H1N1) in France: Implications for future vaccination campaigns. Vaccine, 2014, 32, 2281-2287.	3.8	29
128	Low Alcohol Consumption as a Predictor of Higher CD4+ Cell Count in HIV-Treated Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e148-e150.	2.1	16
129	Predictors of Non-adherence to Methadone Maintenance Treatment in Opioid-dependent Individuals: Implications for Clinicians. Current Pharmaceutical Design, 2014, 20, 4097-4105.	1.9	44
130	Cocoa and Chocolate: Chemistry, Biochemistry, and Beneficial Brain Effects. , 2013, , 389-406.		1
131	Prediction of HIV Drug Resistance Based on Virologic, Immunologic, Clinical, and/or Adherence Criteria in the Stratall ANRS 12110/ESTHER Trial in Cameroon. Clinical Infectious Diseases, 2013, 57, 604-607.	5.8	6
132	Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. International Journal of Cardiology, 2013, 168, 568-569.	1.7	65
133	Health-care-associated bloodstream infections in France. Lancet Infectious Diseases, The, 2013, 13, 656.	9.1	4
134	De jure decriminalisation of cannabis use matters: some recent trends from France. International Journal of Drug Policy, 2013, 24, 634-635.	3.3	7
135	Time to combine intervention with prevention in countries where <scp>HIV</scp> is also driven by hazardous drinking. Addiction, 2013, 108, 221-222.	3.3	1
136	Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods. Expert Review of Anti-Infective Therapy, 2013, 11, 239-250.	4.4	24
137	Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infectious Diseases, The, 2013, 13, 577-586.	9.1	39
138	No condoms for prisoners: accumulating risks of HIV, STI but also hepatitis transmission. Sexually Transmitted Infections, 2013, 89, 310-310.	1.9	1
139	Visiting One's Native Country. Journal of the International Association of Providers of AIDS Care, 2013, 12, 407-413.	1.5	12
140	Self-reported alcohol abuse in <scp>HIV</scp>-infected patients: a better predictor of <scp>HIV</scp> virological rebound than physician's perceptions (<scp>HEPAVIH ARNS CO</scp> 13) Tj ETQq0 0.0 rgBT / Overlock 10		
141	Factors associated with guideline-based hepatitis <scp>C</scp> virus (<scp>HCV</scp>) treatment initiation in <scp>HIV</scp>/<scp>HCV</scp>-coinfected patients: role of comorbidities and physicians' perceptions. HIV Medicine, 2013, 14, 430-436.	2.2	9
142	Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon - Data from the STRATALL ANRS 12110/ESTHER trial. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 347-355.	1.2	6
143	Task Shifting HIV Care in Rural District Hospitals in Cameroon. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 569-576.	2.1	26
144	Time Patterns of Adherence and Long-Term Virological Response to Non-Nucleoside Reverse Transcriptase Inhibitor Regimens in the Stratall Anrs 12110/Esther Trial in Cameroon. Antiviral Therapy, 2013, 18, 29-37.	1.0	20

#	ARTICLE	IF	CITATIONS
145	Expanding Access to Non-Medicalized Community-Based Rapid Testing to Men Who Have Sex with Men: An Urgent HIV Prevention Intervention (The ANRS-DRAG Study). <i>PLoS ONE</i> , 2013, 8, e61225.	2.5	32
146	20-Years of Population-Based Cancer Registration in Hepatitis B and Liver Cancer Prevention in The Gambia, West Africa. <i>PLoS ONE</i> , 2013, 8, e75775.	2.5	14
147	The Role of Adherence in Virological Suppression in Patients Receiving Anti-HBV Analogues. <i>Antiviral Therapy</i> , 2012, 17, 395-400.	1.0	31
148	Proximity to HIV is associated with a high rate of HIV testing among men who have sex with men living in Douala, Cameroon. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 1020-1027.	1.2	10
149	Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 468-477.	1.2	40
150	Performance of HIV care decentralization from the patient's perspective: health-related quality of life and perceived quality of services in Cameroon. <i>Health Policy and Planning</i> , 2012, 27, 301-315.	2.7	34
151	Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. <i>Annals of Oncology</i> , 2012, 23, 882-890.	1.2	107
152	Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy. <i>BMJ Open</i> , 2012, 2, e001155.	1.9	9
153	Reconceptualizing Research on HIV Treatment Outcomes Among Criminalized Groups. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 329-330.	2.1	1
154	Incidence, Medical and Socio-Behavioural Predictors of Psychiatric Events in An 11-Year Follow-Up of HIV-Infected Patients on Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2012, 17, 1079-1083.	1.0	13
155	Obesity-associated gut microbiota is enriched in <i>Lactobacillus reuteri</i> and depleted in <i>Bifidobacterium animalis</i> and <i>Methanobrevibacter smithii</i> . <i>International Journal of Obesity</i> , 2012, 36, 817-825.	3.4	567
156	Empowering HIV testing as a prevention tool: Targeting interventions for high-risk men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 1039-1045.	1.2	14
157	Choice of therapeutic strategies in the context of HIV infection: key role of patient-reported outcomes. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 403-406.	4.4	6
158	Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus/HCV coinfecting patients: one more argument for expanded access to HCV treatment for injecting drug users. <i>Addiction</i> , 2012, 107, 152-159.	3.3	16
159	Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). <i>BMC Health Services Research</i> , 2012, 12, 59.	2.2	9
160	The Macroeconomic Consequences of Renouncing to Universal Access to Antiretroviral Treatment for HIV in Africa: A Micro-Simulation Model. <i>PLoS ONE</i> , 2012, 7, e34101.	2.5	18
161	Adherence as a Predictor of Sexual Behaviors in People Living with HIV/AIDS during the First Year of Antiretroviral Therapy in Rural Cameroon: Data from Stratall ANRS 12110/ESTHER Trial. <i>PLoS ONE</i> , 2012, 7, e36118.	2.5	9
162	Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 1163-1170.	1.2	6

#	ARTICLE	IF	CITATIONS
163	Non-adherence to aspirin in patients undergoing coronary stenting: Negative impact of comorbid conditions and implications for clinical management. Archives of Cardiovascular Diseases, 2011, 104, 306-312.	1.6	14
164	Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: The role of the physician. Drug and Alcohol Dependence, 2011, 116, 228-232.	3.2	28
165	Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination. Vaccine, 2011, 29, 8656-8660.	3.8	17
166	Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infectious Diseases, The, 2011, 11, 825-833.	9.1	83
167	Decentralization of access to antiretroviral therapy in Cameroon: correlates of HIV physicians' knowledge in HIV care. Antiviral Therapy, 2011, 16, 423-428.	1.0	2
168	Individual and Structural Factors Associated With HIV Status Disclosure to Main Partner in Cameroon: ANRS 12-116 EVAL Survey, 2006-2007. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S22-S26.	2.1	13
169	Adherence to Antiretroviral Treatment in HIV-Positive Patients in the Cameroon Context: Promoting the Use of Medication Reminder Methods. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S40-S43.	2.1	30
170	Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. Journal of Viral Hepatitis, 2011, 18, e307-14.	2.0	36
171	Reduced delays in time to first HIV consultation after diagnosis in France in the antiretroviral therapy era: the possible role of a free care system. HIV Medicine, 2011, 12, 383-384.	2.2	1
172	Non Adherence to Thienopyridine after Coronary Stenting. American Journal of Cardiology, 2011, 107, 1866-1867.	1.6	1
173	Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 760-765.	1.6	40
174	Chronic Q Fever Detection in the Netherlands. Clinical Infectious Diseases, 2011, 53, 1170-1171.	5.8	15
175	Higher risk of unsafe sex and impaired quality of life among patients not receiving antiretroviral therapy in Cameroon: results from the EVAL survey (ANRS 12-116). Aids, 2010, 24, S17-S25.	2.2	22
176	The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13) Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 22	2.9	19
177	Psychosocial correlates of inconsistent condom use among HIV-infected patients enrolled in a structured ART interruptions trial in CÔte d'Ivoire: results from the TRIVACAN trial (ANRS 1269). Tropical Medicine and International Health, 2010, 15, 706-712.	2.3	14
178	Quality of life assessment in HIV clinical research in resource-limited settings: better late than never. Tropical Medicine and International Health, 2010, 15, no-no.	2.3	0
179	Prevalence of unsafe sex with one's steady partner either HIV-negative or of unknown HIV status and associated determinants in Cameroon (EVAL ANRS12-116 survey). Sexually Transmitted Infections, 2010, 86, 148-154.	1.9	27
180	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per $\mu$ L in Europe and North America: a pooled cohort observational study. Lancet, The, 2010, 376, 340-345.	13.7	82

#	ARTICLE	IF	CITATIONS
181	Desire for a child among HIV-infected women receiving antiretroviral therapy in Cameroon: results from the national survey EVAL (ANRS 12-116). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 441-451.	1.2	15
182	Quality of Life in HIV Positive Injecting Drug Users. , 2010, , 3705-3725.		0
183	EXPANDED ACCESS TO SEPs AND OTHER HARM REDUCTION MEASURES IN FRANCE. Addiction, 2009, 104, 1447-1448.	3.3	5
184	Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008. Journal of Viral Hepatitis, 2009, 17, 650-60.	2.0	9
185	Delayed first consultation after diagnosis of HIV infection in Cameroon. Aids, 2009, 23, 1015-1019.	2.2	18
186	Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116). Tropical Medicine and International Health, 2008, 13, 1470-1478.	2.3	58
187	Physicians' and patients' adherence to antiretroviral prophylaxis after sexual exposure to HIV: results from South-Eastern France. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 537-541.	1.2	19
188	Depressive Symptoms and Exposure to Efavirenz in West African HIV-Infected Adults. HIV Clinical Trials, 2008, 9, 445-447.	2.0	8
189	20 Years into the Gambia Hepatitis Intervention Study: Assessment of Initial Hypotheses and Prospects for Evaluation of Protective Effectiveness Against Liver Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3216-3223.	2.5	63
190	Impaired Anger Control as an Underappreciated Side Effect of Treatments for Chronic HCV Infection in HIV-HCV Coinfected Patients. Journal of Clinical Gastroenterology, 2008, 42, 92-96.	2.2	18
191	Self-Reported Fatigue and Depressive Symptoms as Main Indicators of the Quality of Life (QOL) of Patients Living with HIV and Hepatitis C: Implications for Clinical Management and Future Research. HIV Clinical Trials, 2007, 8, 320-327.	2.0	68
192	Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. European Journal of Cancer, 2007, 43, 2117-2123.	2.8	127
193	Self-reported side-effects of anti-retroviral treatment among IDUs: A 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). International Journal of Drug Policy, 2007, 18, 288-295.	3.3	35
194	Adding HCV Treatment to HIV Treatment in HIV-HCV Coinfected Patients: The Impact on the Different Dimensions of Fatigue and Self-Reported Side Effects. Journal of Pain and Symptom Management, 2007, 34, 413-421.	1.2	15
195	Immunosuppression and Cancer: A Comparison of Risks in Recipients of Organ Transplants and in HIV-Positive Individuals. Transplantation Proceedings, 2006, 38, 3533-3535.	0.6	41
196	Factors Associated With Nonadherence to Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 477-485.	2.1	96
197	Buprenorphine Use: The International Experience. Clinical Infectious Diseases, 2006, 43, S197-S215.	5.8	125
198	Oral contraception and unprotected sex with occasional partners of women HIV-infected through injection drug use. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2006, 18, 795-800.	1.2	13

#	ARTICLE	IF	CITATIONS
199	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.. Clinical Cancer Research, 2006, 12, 1157-1167.	7.0	495
200	Statistical fallibility and the longevity of popes: William Farr meets Wilhelm Lexis. International Journal of Epidemiology, 2006, 35, 802-805.	1.9	14
201	Longevity of popes and artists between the 13th and the 19th century. International Journal of Epidemiology, 2005, 34, 1435-1436.	1.9	33
202	Factors associated with Efavirenz discontinuation in a large community-based sample of patients. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2004, 16, 558-564.	1.2	50
203	Health-related quality of life and patientâ€“provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2004, 16, 649-661.	1.2	87
204	Drug injection cessation among HIV-infected injecting drug users. Addictive Behaviors, 2004, 29, 1189-1197.	3.0	35
205	Impact of HAART-related side effects on unsafe sexual behaviours in HIV-infected injecting drug users. Aids, 2004, 18, 1321-1325.	2.2	15
206	Failure to maintain adherence to haart in a cohort of French HIV-positive injecting drug users. International Journal of Behavioral Medicine, 2003, 10, 1-14.	1.7	93
207	Reduced incidence of kaposi's sarcoma and of systemic nonâ€“hodgkin's lymphoma in HIVâ€“infected individuals treated with highly active antiretroviral therapy. International Journal of Cancer, 2003, 103, 142-144.	5.1	80
208	Blood Agar and Mycobacterium tuberculosis : the End of a Dogma. Journal of Clinical Microbiology, 2003, 41, 1710-1711.	3.9	46
209	Health-Related Quality of Life After 1 Year of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 38-47.	2.1	113
210	Hospitalization for depressive syndrome in a cohort of HIV-infected patients contaminated through injecting drug use: MANIF 2000 cohort, France, 1995-1999. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2003, 15, 729-734.	1.2	9
211	Intercenter variability and time of onset: two crucial issues in the analysis of risk factors for nosocomial sepsis. Pediatric Infectious Disease Journal, 2003, 22, 599-609.	2.0	33
212	The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination. Aids, 2003, 17, 1096-1099.	2.2	17
213	Nonadherence Among HIV-Infected Injecting Drug Users: The Impact of Social Instability. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S149-S153.	2.1	120
214	Investigation of a Slaughterhouse-Related Outbreak of Q Fever in the French Alps. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 17-21.	2.9	54
215	Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. Aids, 2001, 15, 2441-2444.	2.2	247
216	The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 232-239.	2.1	2

#	ARTICLE	IF	CITATIONS
217	The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 232-239.	2.1	163
218	Clinical, Biologic, and Behavioral Predictors of Early Immunologic and Virologic Response in HIV-Infected Patients Initiating Protease Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 27, 372-376.	2.1	42
219	Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs. <i>International Journal of STD and AIDS</i> , 2001, 12, 324-328.	1.1	27
220	Risks Factors and Prevention of Q Fever Endocarditis. <i>Clinical Infectious Diseases</i> , 2001, 33, 312-316.	5.8	264
221	“Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?” A comparison between patients’ self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. <i>Aids</i> , 2001, 15, 1075-1077.	2.2	38
222	Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. <i>Aids</i> , 2000, 14, 151-155.	2.2	193
223	Cancer risk among men with, or at risk of, HIV infection in southern Europe. <i>Aids</i> , 2000, 14, 553-559.	2.2	105
224	Evaluation of the SIMI system, an experimental computerised network for the surveillance of communicable diseases in Italy. <i>European Journal of Epidemiology</i> , 2000, 16, 941-947.	5.7	21
225	Serum Clara cell protein (CC16) in healthy young smokers. <i>Biomarkers</i> , 2000, 5, 158-164.	1.9	8
226	Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2000, 12, 461-470.	1.2	15
227	Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. <i>Journal of Epidemiology and Community Health</i> , 1999, 53, 4-8.	3.7	87
228	Relationship between HIV-1 viral load and continued drug use in untreated infected injection drug users. <i>Addiction Biology</i> , 1999, 4, 197-202.	2.6	6
229	Risk of invasive cervical cancer among women with, or at risk for, HIV infection. , 1999, 82, 334-337.		90
230	Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active Antiretroviral Therapy. <i>Clinical Therapeutics</i> , 1999, 21, 1313-1320.	2.5	3
231	Risk of invasive cervical cancer among women with, or at risk for, HIV infection. <i>International Journal of Cancer</i> , 1999, 82, 334-337.	5.1	1
232	Mandatory prenatal screening for the human immunodeficiency virus: the experience in south-eastern France of a national policy, 1992-1994. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1998, 105, 269-274.	2.3	19
233	HIV screening for pregnant women in South Eastern France: evolution 1992-1994-1996. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1998, 76, 5-9.	1.1	10
234	A Case-Control Study on Risk Factors for Peyronie’s Disease. <i>Journal of Clinical Epidemiology</i> , 1998, 51, 511-515.	5.0	91



#	ARTICLE	IF	CITATIONS
235	Risk factors for nosocomial sepsis in newborn intensive and intermediate care units. European Journal of Pediatrics, 1996, 155, 315-322.	2.7	58